EP1451209A4 - Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique - Google Patents

Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique

Info

Publication number
EP1451209A4
EP1451209A4 EP02789322A EP02789322A EP1451209A4 EP 1451209 A4 EP1451209 A4 EP 1451209A4 EP 02789322 A EP02789322 A EP 02789322A EP 02789322 A EP02789322 A EP 02789322A EP 1451209 A4 EP1451209 A4 EP 1451209A4
Authority
EP
European Patent Office
Prior art keywords
heptapeptides
hexa
penta
tetra
antiangiogenic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02789322A
Other languages
German (de)
English (en)
Other versions
EP1451209A2 (fr
Inventor
Fortuna Haviv
Michael F Bradley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,540 external-priority patent/US20030119745A1/en
Priority claimed from US10/000,711 external-priority patent/US20030105025A1/en
Priority claimed from US10/263,811 external-priority patent/US20030105022A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP1451209A2 publication Critical patent/EP1451209A2/fr
Publication of EP1451209A4 publication Critical patent/EP1451209A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP02789322A 2001-10-31 2002-10-30 Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique Withdrawn EP1451209A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US263811 1988-10-28
US7 2001-10-31
US10/000,540 US20030119745A1 (en) 2001-10-31 2001-10-31 HEXA- and heptapeptides having antiangiogenic activity
US10/000,711 US20030105025A1 (en) 2001-10-31 2001-10-31 Tri-and tetrapeptides having antiangiogenic activity
US540 2001-10-31
US10/263,811 US20030105022A1 (en) 2001-10-31 2002-10-04 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
PCT/US2002/034760 WO2003037266A2 (fr) 2001-10-31 2002-10-30 Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique

Publications (2)

Publication Number Publication Date
EP1451209A2 EP1451209A2 (fr) 2004-09-01
EP1451209A4 true EP1451209A4 (fr) 2009-06-03

Family

ID=32659830

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02789322A Withdrawn EP1451209A4 (fr) 2001-10-31 2002-10-30 Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique

Country Status (6)

Country Link
EP (1) EP1451209A4 (fr)
JP (1) JP2005512980A (fr)
CA (1) CA2466152A1 (fr)
MX (1) MXPA04004135A (fr)
UY (1) UY27523A1 (fr)
WO (1) WO2003037266A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125260A1 (en) * 2001-10-31 2003-07-03 Fortuna Haviv Tetra-and pentapeptides having antiangiogenic activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764277B2 (en) * 1998-05-22 2003-08-14 Abbvie Inc. Peptide antiangiogenic drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIYASAKI KT ET AL: "Bactericidal Activities of Synthetic Human Leukocyte Cathepsin G-Derived Antibiotic Peptides and Congeners against Actinobacillus actinomycetemcomitans and Capnocytophaga sputigena", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 37, no. 12, December 1993 (1993-12-01), pages 2710 - 2715, XP002523772 *

Also Published As

Publication number Publication date
CA2466152A1 (fr) 2003-05-08
JP2005512980A (ja) 2005-05-12
WO2003037266A3 (fr) 2003-12-11
MXPA04004135A (es) 2004-07-08
UY27523A1 (es) 2003-05-30
EP1451209A2 (fr) 2004-09-01
WO2003037266A2 (fr) 2003-05-08

Similar Documents

Publication Publication Date Title
GB2380983B (en) Modular overhead console assembly
EP1401817A4 (fr) Composes isoquinoline presentant une activite anti-infectieuse
EP1250025A4 (fr) Ecouteurs
AU148399S (en) A headset
HK1065217A1 (en) Headphone
GB0006350D0 (en) Joystick controller
HUP0402171A3 (en) Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
AU143396S (en) Robot
AU8838601A (en) Antiangiogenic agents
EP1450841A4 (fr) Tripeptides, tetrapeptides et pentapeptides a activite anti-angiogenese
AU145539S (en) A headset
PL368745A1 (en) Peptides having antiangiogenic activity
AU144210S (en) Torch
GB2383410B (en) Joystick
EP1451209A4 (fr) Tetra-, penta-, hexa- et heptapeptides possedant une activite anti-angiogenique
GB0324680D0 (en) Cementitios mixtures
GB0010443D0 (en) A floor protector
AU2002353922A1 (en) Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
GB0214196D0 (en) Interference suppression
GB0027235D0 (en) Arc location
GB0026443D0 (en) Multi-land profiler
GB2369386B (en) Improved bucket attachment
SI2177530T1 (sl) Oktapeptid z antiangiogeno aktivnostjo
GB0101116D0 (en) Activity board accessory
GB0105305D0 (en) Headset

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040528

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068900

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20090506

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090805

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1068900

Country of ref document: HK